LynxCare

The core of LynxCare's offering is a platform that uses artificial intelligence (AI) and proprietary clinical Natural Language Processing (NLP) to extract and structure information from siloed and unstructured sources like electronic health records (EHRs). This technology transforms scattered medical text and data into standardized, analysis-ready formats, specifically mapping to the OMOP Common Data Model to ensure interoperability. This process enables healthcare providers and researchers to gain insights into the real-world performance of treatments, which may differ from clinical study results. The platform is deployed across a federated network of hospitals in Europe and North America, allowing for multi-site research while ensuring data privacy and governance by keeping data within the hospital's control.

Since its founding, LynxCare has achieved significant milestones. In 2018, the company underwent a management buyout and incorporated in San Francisco, expanding its presence to the US market. A major growth financing round in June 2022 raised €20 million, led by MTIP and including investors like Elaia, Heran Partners, BTOV, and PMV. This funding, the largest for a digital health company in Belgium at the time, was intended to accelerate international expansion. The company has established partnerships with life sciences firms such as AstraZeneca, Pfizer, and Johnson & Johnson, and is a key contributor to European initiatives like the European Health Data Space (EHDS) and EHDEN.

LynxCare's business model is B2B, serving hospitals and life sciences companies. For hospitals, the platform helps reduce time spent on quality reporting and enhances research capabilities. For life sciences clients, it provides access to high-quality, validated real-world data to support research in areas like oncology and cardiology, analyze medication effectiveness, and speed up the detection of rare diseases.